- Post By : Kumar Jeetendra
- Source: Roche
- Date: 30 Jul,2020
Roche, Basel, Switzerland, has bought FDA approval for its Ventana HER2 Twin ISH DNA Probe Cocktail assay for the detection of the human epidermal convey factor receptor 2 (HER2) biomarker in breast cancer and as a partner diagnostic for Herceptin (trastuzumab) therapy. HER2 is a a must fill biomarker every so continuously chanced on in breast cancer, and its detection and inhibition can abet healthcare experts more effectively take care of this aggressive cancer.
The Ventana HER2 Double ISH DNA Probe Cocktail assay is meant to be executed within exactly the staunch same day, enabling clinicians to assemble results abet quicker than with other general procedures of confirmatory testing for HER2. Results will be read utilizing gentle microscopy, striking off the need for a really knowledgeable fluorescence microscope.
“With this unique VENTANA HER2 Twin ISH assay, Roche continues to attach it up its commitment to arrangement customized healthcare,” says Thomas Schinecker, CEO of Roche Diagnostics. “Quick test results are compulsory in the fight in opposition to cancer and by handing over predominant data on treatment ideas for breast cancer sufferers quicker, this assay will support clinicians in their therapeutic selections.”
For more data, consult with Roche.